VALNEVA SE SP.ADS/2 Total Liabilities
VALNEVA SE SP.ADS/2 total liabilities. Based on the latest financial reports, VALNEVA SE SP.ADS/2 (AYJ0) has total liabilities worth €307.15 Million EUR (≈ $359.10 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See AYJ0 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of VALNEVA SE SP.ADS/2 (2021–2025)
Total liabilities of VALNEVA SE SP.ADS/2 from 2021 to 2025. This chart illustrates how VALNEVA SE SP.ADS/2's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of VALNEVA SE SP.ADS/2 to see how much of total assets are deployed in long-term investments.
VALNEVA SE SP.ADS/2 Competitors by Total Liabilities
The table below lists competitors of VALNEVA SE SP.ADS/2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ooma Inc
NYSE:OOMA
|
USA | $130.97 Million |
|
El Pollo Loco Holdings Inc
NASDAQ:LOCO
|
USA | $306.62 Million |
|
Datamatics Global Services Limited
NSE:DATAMATICS
|
India | Rs7.08 Billion |
|
Eson Precision Ind Co Ltd
TW:5243
|
Taiwan | NT$5.47 Billion |
|
Malam Team
TA:MLTM
|
Israel | ILA1.89 Billion |
|
Gresgying Digital Energy Technology Co Ltd
SHG:600212
|
China | CN¥2.09 Billion |
|
Shanghai Kinlita Chemical Co
SHE:300225
|
China | CN¥506.06 Million |
|
Juniper Hotels Ltd
NSE:JUNIPER
|
India | Rs16.14 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down VALNEVA SE SP.ADS/2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VALNEVA SE SP.ADS/2 total assets.
Liquidity & Leverage Metrics
VALNEVA SE SP.ADS/2 Total Liabilities Ratios Explained
VALNEVA SE SP.ADS/2 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VALNEVA SE SP.ADS/2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VALNEVA SE SP.ADS/2 (2021–2025)
The table below shows the annual total liabilities of VALNEVA SE SP.ADS/2 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €292.67 Million ≈ $342.16 Million |
-8.19% |
| 2024-12-31 | €318.78 Million ≈ $372.69 Million |
-3.93% |
| 2023-12-31 | €331.81 Million ≈ $387.93 Million |
-17.37% |
| 2022-12-31 | €401.55 Million ≈ $469.45 Million |
-37.92% |
| 2021-12-31 | €646.77 Million ≈ $756.14 Million |
-- |
About VALNEVA SE SP.ADS/2
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more